check_circleStudy Completed
Erectile Dysfunction
Bayer Identifier:
12805
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy
Trial purpose
The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Levitra in routine treatment of erectile dysfunction. Furthermore, the data collection particularly focuses on the experience of the patient and his satisfaction with the treatment. Treatment naive patients as well as pre-treated patients will be included in the study.The maximum observation period per patient is 12 months.Besides the physician's documentation, the patient should fill out a questionnaire at every visit. The questionnaires will be handed out and collected by the physician. Furthermore, an additional questionnaire for the patient's partner can be distributed at each visit in case the partner is willing to participate.
Key Participants Requirements
Sex
MaleAge
18 - N/ATrial summary
Enrollment Goal
7293Trial Dates
March 2007 - April 2010Phase
N/ACould I Receive a placebo
NoProducts
Levitra (Vardenafil, BAY38-9456)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, France | |
Completed | Many Locations, Hungary | |
Completed | Many Locations, Malaysia | |
Completed | Many Locations, Saudi Arabia | |
Completed | Many Locations, Singapore | |
Completed | Many Locations, Thailand | |
Completed | Many Locations, South Africa | |
Completed | Many Locations, South Korea | |
Completed | Many Locations, Germany | |
Completed | Many Locations, China | |
Completed | Many Locations, Spain | |
Completed | Many Locations, Croatia | |
Completed | Many Locations, Indonesia | |
Completed | Many Locations, Poland | |
Completed | Many Locations, Sweden |
Primary Outcome
- Physician's assessment of safety (incidence of adverse events)date_rangeTime Frame:During observation periodenhanced_encryptionYesSafety Issue:
Secondary Outcome
- Severity of ED symptomsdate_rangeTime Frame:End of studyenhanced_encryptionNoSafety Issue:
- General quality of partnership as assessed by patientdate_rangeTime Frame:Initial visit and after 3, 6, 9 and 12 monthsenhanced_encryptionNoSafety Issue:
- General quality of partnership as assessed by partnerdate_rangeTime Frame:Initial visit and after 3, 6, 9 and 12 monthsenhanced_encryptionNoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A